Submit an Article
Submit Your Best Content to ISPE
ISPE is a member association and we rely on our members to submit their best work to us, to share their technical knowledge with the industry at large. Whether you write a short blog or contribute to creating a Guidance Document, there are opportunities to submit content on a variety of levels.
With a short lead time to publish and no editorial calendar, the ISPE blog, iSpeak, is a great opportunity to publish content that has a wide appeal to the pharmaceutical and biopharmaceutical industry including: interviews, opinion pieces, technical content, check lists, how to’s, series, etc. Guidelines include:
- Minimum 700 words
- Focused topic, keyword or phrase
- Supported multimedia options include: images, charts, video, infographics, etc.
- Byline including headshot, name, title, and company
Submit your blog post to iSpeak@ispe.org.
Pharmaceutical Engineering Magazine
Pharmaceutical Engineering is always looking for articles! You can submit different types of articles, ranging from an opinion piece to a technical article. Click here for a summary of different article types.
What Types of Articles Is Pharmaceutical Engineering Looking For?
Guest editorial: ≤ 1,000 words
Short, thought-provoking articles that provide a personal perspective on contemporary issues, hot topics, or controversies.
Perspective/feature: ≤ 1,500 words, approx. 2 figures
Recent industry developments, strategic issues, technical developments, trends, or innovative solutions. These articles should stimulate debate, present new models or hypotheses, speculate on the meaning and interpretation of new data, or outline suggestions for future experiments.
Technical article: 5,000 words, approx. 5 figures
Define and demonstrate global best practices in engineering and design, product development, technology transfer, manufacturing process development and scale-up, commercial manufacturing, quality and compliance, and product life cycle management.
Case study: 4,000 words, approx. 5 figures
New approaches to industry problems. Describe the method, process, and technology; discuss any challenges encountered; and provide a balanced comparison of this approach vs. other more established methods.
Research article: 5,000 words, approx. 5 figures
Innovative methods and techniques covering any aspect of the pharmaceutical industry. Must emphasize scientific rigor and reproducible results, with conclusions supported by adequate evidence.
Questions about Pharmaceutical Engineering Article Types or Where Your Article Could Fit?
Please contact Susan Sandler, Editorial Director.
How to Avoid Plagiarism
And Properly Cite the Work of Others
Plagiarism is using another person’s work—copyrighted or not—and representing it as the product of your own effort. This does not mean that you can’t cite to the work of others in your article—you just need to make sure that you do it the right way.
You can avoid plagiarism and properly cite to another source’s work by revising and restating the idea, and providing a numbered endnote reference that cites to the material you have restated.
The other option is to use a direct quote from the source, then add a reference and cite the source from which you copied the text.
Here are some examples to help you see the difference:
The emergence of "big data" has allowed pharmaceutical organizations to harness the vast amount of information they generate. 
"Big data" has allowed pharmaceutical organizations to harness the information they generate. 
Revise and restate
As metrics and statistics have evolved into “big data,” the pharmaceutical industry has learned how to tap the enormous reservoirs of information it produces. 
As Ingram et al. noted, “The emergence of ‘big data’ has allowed pharmaceutical organizations to harness the vast amount of information they generate. “ 
1. Ingram, Marzena, et al. “Manufacturing Excellence Utilizing a Life Cycle Approach.” Pharmaceutical Engineering 37, no. 5 (September-October 2017): 69–69.
Why is plagiarism wrong—even if the material is from a public domain source? Because Pharmaceutical Engineering publishes original thought, research, and content. If an article reuses too much information from another source (even when properly cited), it would not be original. Citing the work of others is also the right way to give others credit for their ideas. Finally, when the uncited material is copyrighted, reusing it without citation and permission could violate the copyright laws in the US and in other countries.
Authors who have published books or articles usually do not own the copyright to those materials. Most publishers, however, grant authors the right to reuse their published work (see the Taylor and Francis and Elsevier author policies as examples). If your article includes text or graphics from a work you published elsewhere, be sure that the quoted material does not exceed the bounds of your agreement with the initial publisher. You must also supply a credit line/attribution to document the material’s source and copyright holder; this text is usually supplied by the publisher.
According to the Copyright Clearance Center, “copyright infringement occurs when a copyrighted work is reproduced, distributed, performed, publicly displayed, or made into a derivative work without the permission of the copyright owner.”2-3 Copyright infringement can have serious legal, financial, and professional consequences.
Using text copied from other sources
Even when you properly cite content that you want to include in your article, there can still be problems with copyright infringement. This usually has to do with how much content you can safely include without violating the original publisher’s copyright. In the US, this is called “fair use” and it allows “limited” use of copyright-protected works for discussion or analysis. In a scholarly or technical work, you can use “short passages” for illustration, comment, or clarification.4 In both cases, copied material must be marked as a quotation, and the source must be cited.
It is also alright to cite to content that is in the public domain: this means works where the copyright expired or works that have been published without copyright protection. You still have to provide the citation and use quotation marks when you are using content verbatim. Here are some examples:
- In the United States, most (but not all) work published by the federal government is in the public domain.
- Works produced by United Kingdom departments and agencies may be available under an open government license;5 if not, they may be subject to Crown Copyright.
- Most European Union documents,6 including EurLex data,7 may be used without permission provided the source is acknowledged.
- 1. United States Copyright Office. “Copyright in General.” https://www.copyright.gov/help/faq/faq-general.html
- 2. Copyright Clearance Center. Copyright FAQ. “What Is ‘Copyright Infringement’?” http://support.copyright.com/index.php?action=article&id=240
- 3. United States Copyright Office. “Copyright in Derivative Works and Compilations.” Circular 14. https://www.copyright.gov/circs/circ14.pdf
- 4. United States Copyright Office. “More Information on Fair Use.” https://www.copyright.gov/fair-use/more-info.html
- 5. United Kingdom National Archives. “Licensing for Re-Use.” http://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/licensing-for-re-use
- 6. Official Journal of the European Union. “Commission Decision of 12 December 2011 on the Reuse of Commission Documents.” 14 December 2011. http://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX%3A32011D0833
- 7. European Union. Copyright Notice. http://eur-lex.europa.eu/content/legal-notice/legal-notice.html#droits